Table 1.
Effects of pravastin in animal models.
| Preclinical model | Agent | Results | Reference |
|---|---|---|---|
| CBA/J × DBA/2 mice | Pravastatin (20 ug/kg) | ↓ sFlt-1 ↓ Hypersensitivity to Ang II ↑ VEGF | Ahmed et al., 2010 |
| CD-1 mouse injected with adenovirus carrying sFlt-1 | Pravastatin (5 mg/kg/d) | ↓sFlt-1 Restoration of glucose response in females | McDonnold et al., 2014 |
| CD-1 mouse injected with adenovirus carrying sFlt-1 | Pravastatin (5 mg/kg/d) | Regularization of impaired vestibular function, balance and coordination linked with preeclampsia | Carver et al., 2014 |
| CD-1 mouse injected with adenovirus carrying sFlt-1 | Pravastatin (5 mg/kg/d) | ↓ sFlt-1 ↓ sEng ↓ Overexpression of TGF-β in placenta ↓ HIF-1α | Saad et al., 2014 |
| CD-1 mouse injected with adenovirus carrying sFlt- | Pravastatin (5 mg/kg/d) | ↑ eNOS in the aorta | Fox et al., 2011 |
| CD-1 mouse injected with adenovirus carrying sFlt-1 | Pravastatin (5 mg/kg/d) | ↓ sFlt-1 ↑ PIGF ↓ Hypertension ↓ Proteinuria | Kumasawa et al., 2011 |
| CD-1 mouse injected with adenovirus carrying sFlt-1 | Pravastatin (5 mg/kg/d) | ↓ sFlt-1 ↓ Contractile response to phenylephrine ↑ Vasorelaxant response to ACh | Costantine et al., 2010 |
| C1q deficient (C1q-/-) mouse | Pravastatin (5 mg/d) | ↑ VEGF ↓ sFlt-1 ↓ Albumin creatinine ratio (ACR) ↓ STAT-8 ? Matrix metalloproteinase (MMP) activity Normal aortic ring response to AngII | Singh et al., 2011 |
| Reduced utero-placental perfusion pressure (RUPP) rats | Pravastatin (1 mg/kg/d) | ↓ MAP ↓ sFlt-1 ↑ VEGF ↓ sFlt-1/VEGF ratio ↓ Thiobarbituric acid reactive substances ↑ Total antioxidant capacity ↓ Endothelial tube formation No effect on HO-1 expression | Bauer et al., 2013 |